Recently Featured

LG AI Research and D&D Pharmatech Sign Agreement for Oral Peptide Drugs

June 21, 2026
LG AI Research and D&D Pharmatech have formalized a strategic partnership aimed at advancing the development of next-generation oral peptide drugs. This collaboration was announced following a signing ceremony at the LG Twin Towers in Yeouido, Seoul, marking a significant milestone in the pharmaceutical landscape. The agreement underscores the growing interest in oral peptide formulations,…

AI’s Growing Appetite for Power: A Public Health Concern

June 21, 2026
AI technologies are revolutionizing the pharmaceutical landscape, enhancing drug discovery and refining diagnostic processes. However, this rapid advancement comes with a significant and often overlooked consequence: an increased strain on essential resources such as electricity and water. As AI systems demand more power to function effectively, the sustainability of our energy and water infrastructure is…

Super-potent synthetic opioids called nitazenes are spreading across the U.S.

June 21, 2026
Super-potent synthetic opioids known as nitazenes are increasingly infiltrating the U.S. drug market, raising significant concerns among healthcare professionals and regulatory bodies. These substances, which are structurally related to traditional opioids, exhibit a potency that can exceed that of fentanyl, posing heightened risks of overdose and death. The emergence of nitazenes reflects a broader trend…

Novo’s Success with Oral Wegovy Driven by Familiarity, Says Spherix

June 21, 2026
Name recognition and “familiarity” with Novo Nordisk’s oral Wegovy have significantly contributed to its rapid market uptake, particularly in its competition against Lilly’s oral GLP-1 treatment, Foundayo. This insight comes from Spherix analyst Jim Hickey, who regularly conducts surveys with healthcare professionals prescribing these treatments. The data indicates that physicians’ existing awareness of Wegovy plays…

Ongoing Cases